ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 181 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $123 | -88.6% | 10,987 | -78.3% | 0.00% | -100.0% |
| Q2 2023 | $1,082 | -41.9% | 50,557 | +9.8% | 0.00% | -60.0% |
| Q1 2023 | $1,862 | +100.2% | 46,040 | +130.4% | 0.01% | +150.0% |
| Q4 2022 | $930 | -99.9% | 19,983 | -0.8% | 0.00% | -33.3% |
| Q3 2022 | $1,045,000 | +22.1% | 20,138 | +11.2% | 0.00% | +50.0% |
| Q2 2022 | $856,000 | -19.1% | 18,111 | +21.9% | 0.00% | 0.0% |
| Q1 2022 | $1,058,000 | -3.4% | 14,858 | +1.5% | 0.00% | 0.0% |
| Q4 2021 | $1,095,000 | +32.6% | 14,642 | +0.7% | 0.00% | 0.0% |
| Q3 2021 | $826,000 | +27.7% | 14,543 | -1.0% | 0.00% | +100.0% |
| Q2 2021 | $647,000 | -11.0% | 14,693 | -0.4% | 0.00% | -50.0% |
| Q1 2021 | $727,000 | +16.7% | 14,748 | -0.3% | 0.00% | +100.0% |
| Q4 2020 | $623,000 | -8.1% | 14,792 | -0.1% | 0.00% | -50.0% |
| Q3 2020 | $678,000 | -0.4% | 14,813 | +9.2% | 0.00% | 0.0% |
| Q2 2020 | $681,000 | -1.2% | 13,562 | +1.3% | 0.00% | 0.0% |
| Q1 2020 | $689,000 | -12.3% | 13,391 | +5.3% | 0.00% | 0.0% |
| Q4 2019 | $786,000 | -55.7% | 12,723 | -56.9% | 0.00% | -60.0% |
| Q3 2019 | $1,774,000 | +69.0% | 29,517 | +137.2% | 0.01% | +66.7% |
| Q2 2019 | $1,050,000 | -8.4% | 12,443 | +3.7% | 0.00% | -25.0% |
| Q1 2019 | $1,146,000 | +45.8% | 12,002 | +8.2% | 0.00% | +33.3% |
| Q4 2018 | $786,000 | -15.2% | 11,092 | +2.2% | 0.00% | 0.0% |
| Q3 2018 | $927,000 | -19.3% | 10,849 | +9.4% | 0.00% | -25.0% |
| Q2 2018 | $1,149,000 | +52.8% | 9,913 | +6.6% | 0.00% | +33.3% |
| Q1 2018 | $752,000 | +43.8% | 9,299 | +4.4% | 0.00% | +50.0% |
| Q4 2017 | $523,000 | +27.9% | 8,906 | +2.0% | 0.00% | +100.0% |
| Q3 2017 | $409,000 | +35.0% | 8,730 | +3.8% | 0.00% | 0.0% |
| Q2 2017 | $303,000 | +25.7% | 8,410 | +7.3% | 0.00% | 0.0% |
| Q1 2017 | $241,000 | -3.6% | 7,840 | +5.1% | 0.00% | 0.0% |
| Q4 2016 | $250,000 | -81.1% | 7,460 | -75.7% | 0.00% | -85.7% |
| Q2 2014 | $1,324,000 | – | 30,731 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 511,186 | $43,686,000 | 11.23% |
| GREAT POINT PARTNERS LLC | 210,400 | $17,981,000 | 2.80% |
| ARMISTICE CAPITAL, LLC | 456,000 | $38,970,000 | 2.34% |
| Matarin Capital Management, LLC | 210,208 | $17,964,376,000 | 1.16% |
| Sapphire Star Partners LP | 8,168 | $698,000 | 0.70% |
| Granahan Investment Management | 103,320 | $8,830,000 | 0.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 867,500 | $74,137,000 | 0.44% |
| 361 CAPITAL LLC | 19,040 | $1,627,000 | 0.35% |
| ALGERT GLOBAL LLC | 17,922 | $1,532,000 | 0.33% |
| AlphaMark Advisors, LLC | 9,310 | $796,000 | 0.32% |